Pfizer (GB:0Q1N)
LSE:0Q1N
0Q1N Stock Chart & Stats
$26.87
-$0.50(-1.83%)
At close: 4:00 PM EST
$26.87
-$0.50(-1.83%)
Day’s Range― - ―
52-Week Range$21.20 - $28.88
Previous CloseN/A
Volume69.09K
Average Volume (3M)76.02K
Market Cap
$153.13B
Enterprise Value$219.29B
Total Cash (Recent Filing)$13.60B
Total Debt (Recent Filing)$67.42B
Price to Earnings (P/E)18.2
Beta0.82
Next Earnings
May 05, 2026EPS Estimate
0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.66
Shares Outstanding5,688,356,000
10 Day Avg. Volume60,324
30 Day Avg. Volume76,018
Financial Highlights & Ratios
PEG Ratio-4.31
Price to Book (P/B)1.64
Price to Sales (P/S)2.26
P/FCF Ratio15.59
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue3.50
Enterprise Value/Gross Profit4.98
Enterprise Value/Ebitda13.07
Forecast
1Y Price Target
$29.12Price Target Upside8.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
EPS Forecast (FY)2.96
Revenue Forecast (FY)$61.17B
Bulls Say, Bears Say
Bulls Say
Financial Performance And MarginsEarnings exceeded expectations due to stronger vaccine sales and improved gross and operating margin efficiencies, supporting the company's ability to fund pipeline advancement and business development.
Obesity Portfolio And M&AAcquisition of Metsera plus VESPER-3 topline and the potential MET-233i combination position the company with a differentiated fixed-dose GLP-1 and amylin offering that could enhance competitiveness in obesity treatment.
Patent ProtectionCourt ruling allowing spectroscopy-based expert testimony strengthens the defense of the Vyndamax polymorph patent and improves prospects for extended exclusivity or a favorable settlement.
Bears Say
Clinical Data UncertaintyOutstanding questions about placebo effects and patient discontinuation in the VESPER-3 topline raise uncertainty about MET-097i's tolerability and full clinical benefit until the complete dataset is available.
Generic Litigation RiskGeneric challengers pursuing invalidity arguments and at least one filer arguing obviousness create legal uncertainty that could threaten exclusivity for tafamidis-related products.
Market Pricing And Revenue ErosionPrice cuts in the GLP-1 market, potential revenue erosion from products losing exclusivity, and softer sales in certain key drugs could pressure near-term revenue and valuation.
Pfizer News
0Q1N FAQ
What was Pfizer’s price range in the past 12 months?
Pfizer lowest share price was $21.20 and its highest was $28.88 in the past 12 months.
What is Pfizer’s market cap?
Pfizer’s market cap is $153.13B.
When is Pfizer’s upcoming earnings report date?
Pfizer’s upcoming earnings report date is May 05, 2026 which is in 21 days.
How were Pfizer’s earnings last quarter?
Pfizer released its earnings results on Feb 03, 2026. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.567 by $0.093.
Is Pfizer overvalued?
According to Wall Street analysts Pfizer’s price is currently Undervalued.
Does Pfizer pay dividends?
Pfizer does not currently pay dividends.
What is Pfizer’s EPS estimate?
Pfizer’s EPS estimate is 0.72.
How many shares outstanding does Pfizer have?
Pfizer has 5,688,356,000 shares outstanding.
What happened to Pfizer’s price movement after its last earnings report?
Pfizer reported an EPS of $0.66 in its last earnings report, beating expectations of $0.567. Following the earnings report the stock price went down -2.872%.
Which hedge fund is a major shareholder of Pfizer?
Currently, no hedge funds are holding shares in GB:0Q1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pfizer Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.12 (8.37% Upside)
$29.12 (8.37% Upside)
Blogger Sentiment
Bullish
GB:0Q1N Sentiment 90%
Sector Average 71%
Sector Average 71%
News Sentiment
Bearish
Bullish news 25%
Bearish news 75%
Bearish news 75%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.74%
12-Months-Change
Fundamentals
Return on Equity
8.67%
Trailing 12-Months
Asset Growth
-2.45%
Trailing 12-Months
Company Description
Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
0Q1N Company Deck
0Q1N Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong positives — better‑than‑expected adjusted EPS, margin expansion, meaningful cost‑savings realization, promising obesity (PF‑3944) clinical readouts with differentiated monthly dosing, robust activity on pivotal studies and approvals, and strategic acquisitions that are already contributing revenue growth. Offsetting these strengths are near‑term challenges: modest overall revenue decline (driven largely by a pronounced COVID revenue drop), a sizable $4.4 billion impairment reflecting portfolio reprioritization, upcoming LOE pressure (including ~ $1.5 billion revenue compression projected in 2026), and some GAAP volatility in the quarter. On balance, the company reinforced a clear strategic plan, reaffirmed 2026 guidance, and emphasized productivity/AI initiatives and reinvestment into high‑impact R&D, suggesting the positives materially outweigh the near‑term negatives.View all GB:0Q1N earnings summaries0Q1N Revenue Breakdown
97.79% Biopharma
0.00% PC1
0.00% Pfizer Ignite
2.21% Other business activities
0Q1N Stock 12 Month Forecast
Average Price Target
$29.12
▲(8.37% Upside)
Technical Analysis
Options Prices
Currently, No data available
---